The development of the freelight chain assays by Professors Bradwell and Drayson has had significant impact on the clinical management of patients with B cell lymphoid neoplasias and has led to changes in clinical practice and commercial impact through the success of the Binding Site and the formation of Serascience.
The SFLC test has been adopted as a prognostic marker for the whole range of B lymphoid cancers and premalignant conditions. More recently it has been adopted as a prognostic marker for survival in normal populations.
The Binding Site was formed in 1982 to manufacture and supply antibodies, alongside developing a series of diagnostic tests. Following the development of the SFLC test the Binding Site incorporated the technology as a key part of its product portfolio. In 2012, 360,000 SFLC tests were sold each month worldwide.
A new University spinout company, SeraScience, was formed in 2011 to commercialise the SFLC assay. The company has successfully developed a new range of “point of care tests” for FLC, which will mean that the SFLC assay can be undertaken within the clinic, providing rapid clinical assessment and immediate information for the patient and clinical teams.